Sanofi (ADR) (NYSE:SNY)

Prescription drugs

Pfizer Pays a Big Premium for Medivation

In one of the longest running bidding wars in recent times, Pfizer Inc. (NYSE: PFE) has finally reeled in cancer-drug maker Medivation Inc. (NASDAQ: MDVN) for a whopping $81.50 a ...
Read Full Story »
money

How Much Medivation Can Really Fetch in a Buyout

Medivation Inc. (NASDAQ: MDVN) has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, ...
Read Full Story »
Warren Buffett square

Major Changes Seen in Warren Buffett and Berkshire Hathaway Stocks: Apple, Wal-Mart, Phillips 66, Deere and More

Berkshire Hathaway Inc. (NYSE: BRK-A) has released its public equity holdings as of June 30, 2016. What makes this so interesting for Warren Buffett fans, outside of Buffett being one ...
Read Full Story »
bigger fish

How Medivation Shareholders May Lose Big by Poison Pill in Hostile Takeover Fight With Sanofi

Sanofi S.A. (NYSE: SNY) wants Medivation Inc. (NASDAQ: MDVN) and it is going to extreme lengths to get it. Usually the term “hostile takeover” is an exaggeration, but in this case ...
Read Full Story »
mosquito

7 Companies in the Fight to Defeat the Zika Virus

In 2016, it is the Zika virus that has the public worried about the next pandemic. Past scares have been around Ebola, E. coli, SARS, mad cow, swine flu and ...
Read Full Story »
Warren Buffett

Major Changes Seen in Warren Buffett and Berkshire Hathaway Stock Holdings — Including Apple

Being the wealthiest man in the world on paper tends to draw some attention. This is why investors and outsiders watch new equity investment positions taken by, or sold by, ...
Read Full Story »
Prescription drugs

Analysts Adjust Predictions on Medivation Buyout Price

One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the position that Medivation Inc. (NASDAQ: MDVN) found itself in after ...
Read Full Story »
Warren Buffet

Major Changes Seen in Warren Buffett and Berkshire Hathaway Stocks for 2016

Warren Buffett has now released the official equity holdings of Berkshire Hathaway Inc. (NYSE: BRK-A) as of December 31, 2016. That makes this the official Buffett stocks for 2016, but ...
Read Full Story »
investing

Major Changes Seen in Warren Buffett and Berkshire Hathaway Stock Holdings

Warren Buffett and Berkshire Hathaway Inc. (NYSE: BRK-A) have released their official equity holdings of Berkshire Hathaway as of September 30, 2015. 24/7 Wall St. has followed this trend for ...
Read Full Story »
Automatic Inspection Machine - Ampules

Why RBC Is Now So Negative Against MannKind

MannKind Corp. (NASDAQ: MNKD) remains one of the most controversial bio-health stocks of them all. Its stock was under pressure on Wednesday on news of a key analyst downgrade. The ...
Read Full Story »
Buffet

Key Changes in Warren Buffett and Berkshire Hathaway Stock Holdings

Warren Buffett and Berkshire Hathaway Inc. (NYSE: BRK-A) have released the official equity holdings of Berkshire Hathaway as of June 30, 2015. It has been the case for years now ...
Read Full Story »
Biotechnology word cloud

Have Analysts Fully Priced in Praluent to Regeneron?

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) announced last Friday that the U.S. Food and Drug Administration (FDA) approved Praluent (alirocumab) Injection. Praluent is indicated as an adjunct ...
Read Full Story »
Prescription drugs

Are Cancer Drugs Becoming Too Costly for Their Effectiveness?

When the American Society of Clinical Oncology (ASCO) decided to create a rating scale for cancer drugs, it certainly must have expected to get some pushback. The group’s initial version ...
Read Full Story »
145922793

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

This coming week is likely to be a serious one in the fight against cholesterol. This covers a new class of drugs in the PCSK9 classification, and FDA panels are ...
Read Full Story »
investing

Has MannKind Stock Finally Bottomed Out?

MannKind Corp. (NASDAQ: MNKD) is just about as controversial of a company as you will find today when it comes to biotech and pharma. Its recently launched Afrezza has had ...
Read Full Story »